⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SCNX News
Scienture Holdings, Inc. Common Stock
SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team
globenewswire.com
SCNX
SCIENTURE to Present at The Small Cap Showcase & WTR Insights on June 9, 2026, in NYC
accessnewswire.com
SCNX
SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041
globenewswire.com
SCNX
Form 8-K
sec.gov
SCNX
Form 8-K
sec.gov
SCNX
SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion
globenewswire.com
SCNX
Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D Pipeline
globenewswire.com
SCNX
SCIENTURE Announces Third Patent Grant for ARBLI™ (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041
globenewswire.com
SCNX
Form 8-K
sec.gov
SCNX
Form 8-K
sec.gov
SCNX